AbbVie preps for an onslaught of Humira biosimilars in 2023, with Skyrizi and Rinvoq to fill the gap for now

Unveiled Friday morning, AbbVie’s Q3 results and earnings call show a company bracing for what could be steep Humira losses with the coming of biosimilar competitors early next year, even as the rest of its immunology franchise outpaces initial expectations.

Beginning in January, AbbVie’s and the world’s best-selling drug Humira...

Click to view original post